Fierce Biotech: 2nd Drug Development Forum (EXL)

Sep 25 2017 8:00 AM

Hosted by: Blackman Theatre
Blackman Theatre
360 Huntington Avenue , Boston, Massachusetts 02115

The FDA approved only 22 new drug candidates in 2016 — less than half of the prior year, and the lowest level since 2010. The IPO market has collapsed to its lowest level since 2009. In the face of this regulatory and financial uncertainty, biotech companies must increasingly rely on creative deal-making and the discovery of new indications for established products.